Cancer-Killing virus joins forces with immunotherapy in new trial
NCT ID NCT06889493
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a cancer-killing virus (SVV-001) injected directly into tumors, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 36 adults with advanced neuroendocrine tumors that have worsened after standard treatment. The main goals are to find the safest dose and dosing schedule, and to see if the combination can control the disease. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Seneca Valley Virus (SVV-001) plus nivolumab and ipilimumab
What this could lead to
If successful, this could point toward a new treatment option for people with advanced neuroendocrine tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 36 participants, so safety and dosing are still being figured out. The combination may cause significant side effects or may not shrink tumors effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact